A Study of Patients With HER2-Positive Metastatic Breast Cancer
NCT ID: NCT00105456
Last Updated: 2010-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1000 participants
OBSERVATIONAL
2003-03-31
2009-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
HER2-positive Breast Cancer Registry
NCT06603597
Omission of Radiation in Patients With Her-2 Positive Breast Cancer
NCT03460067
microRNA of Human Epidermal Growth Factor Receptor 2 （HER2）Positive Patient Treated With Herceptin
NCT02656589
Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast Cancer
NCT06358625
Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?
NCT02286843
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signed Authorization for the Use and Disclosure of Health Information document
* HER2-positive breast cancer
* Initial diagnosis of metastatic (Stage IV) breast cancer within 6 months prior to enrollment
* Availability of cancer-specific historical data points in the patient's medical records
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genentech, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Genentech, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Isaiah Dimery, M.D.
Role: STUDY_DIRECTOR
Genentech, Inc.
References
Explore related publications, articles, or registry entries linked to this study.
Yardley DA, Tripathy D, Brufsky AM, Rugo HS, Kaufman PA, Mayer M, Magidson J, Yoo B, Quah C, Ulcickas Yood M. Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer. 2014 May 27;110(11):2756-64. doi: 10.1038/bjc.2014.174. Epub 2014 Apr 17.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H2757n
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.